Hair Follicle as a Source of Pigment-Producing Cells for Treatment of Vitiligo: An Alternative to Epidermis?
- PMID: 33034877
- PMCID: PMC7710812
- DOI: 10.1007/s13770-020-00284-2
Hair Follicle as a Source of Pigment-Producing Cells for Treatment of Vitiligo: An Alternative to Epidermis?
Abstract
To discuss the advantages and limitations of hair follicle-derived cell transplantation (FCT) in vitiligo, compared to the epidermal cell transplantation (ECT), and the knowledge gap which is required to be bridged. The papers relevant to the purpose was reviewed. Surgical approaches for treating vitiligo are based on the idea of replenishing lost melanocytes. Skin and hair follicles as the main sources of melanocytes have been applied for this purpose transferring the whole tissue or tissue-derived cell suspension to the vitiligo lesions. Considering the differences between hair follicle and epidermis in terms of the constituting cell populations, phenotype and function of melanocytes, and micro-environmental factors, different response of vitiligo patients to treatment with FCT or ECT would be expected theoretically. However, there is currently a lack of evidence on such a difference. However, ECT appears to be a more feasible, less time-consuming, and more comfortable treatment for both physicians and patients. Although the current evidence has not shown a significant difference between ECT and FCT in terms of efficacy, ECT appears to be more feasible specifically in the treatment of large lesions. However, further randomized controlled clinical trials with larger sample sizes and longer follow-up durations are required to be conducted to draw a definite conclusion on comparing FCT with ECT in terms of the safety, efficacy, durability of the therapeutic effects, and indications in vitiligo patients.
Keywords: Cell therapy; Hair follicle; Melanocyte; Regenerative medicine; Vitiligo.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Similar articles
-
Hair follicle-derived melanocyte transplant as a promising treatment strategy for vitiligo.Stem Cell Res Ther. 2025 Jun 3;16(1):280. doi: 10.1186/s13287-025-04410-6. Stem Cell Res Ther. 2025. PMID: 40462233 Free PMC article.
-
Different populations of melanocytes are present in hair follicles and epidermis.Pigment Cell Res. 1996 Dec;9(6):304-10. doi: 10.1111/j.1600-0749.1996.tb00122.x. Pigment Cell Res. 1996. PMID: 9125754
-
Repigmentation through Melanocyte Regeneration in Vitiligo.Dermatol Clin. 2017 Apr;35(2):205-218. doi: 10.1016/j.det.2016.11.015. Dermatol Clin. 2017. PMID: 28317529 Review.
-
Noncultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo.Br J Dermatol. 2011 Jun;164(6):1241-6. doi: 10.1111/j.1365-2133.2011.10234.x. Br J Dermatol. 2011. PMID: 21275943
-
Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.J Eur Acad Dermatol Venereol. 2025 Mar;39(3):498-511. doi: 10.1111/jdv.20311. Epub 2024 Sep 11. J Eur Acad Dermatol Venereol. 2025. PMID: 39258892 Free PMC article. Review.
Cited by
-
Comparative study between combined follicular and epidermal cell suspension versus epidermal cell suspension in treatment of stable vitiligo.Arch Dermatol Res. 2025 Feb 12;317(1):388. doi: 10.1007/s00403-025-03813-y. Arch Dermatol Res. 2025. PMID: 39937279
-
Hair follicle-derived melanocyte transplant as a promising treatment strategy for vitiligo.Stem Cell Res Ther. 2025 Jun 3;16(1):280. doi: 10.1186/s13287-025-04410-6. Stem Cell Res Ther. 2025. PMID: 40462233 Free PMC article.
-
Management of Stable Vitiligo-A Review of the Surgical Approach.J Clin Med. 2023 Mar 2;12(5):1984. doi: 10.3390/jcm12051984. J Clin Med. 2023. PMID: 36902772 Free PMC article. Review.
-
Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.Front Med (Lausanne). 2025 Jan 15;11:1510363. doi: 10.3389/fmed.2024.1510363. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39882529 Free PMC article. Review.
-
Management of the refractory vitiligo patient: current therapeutic strategies and future options.Front Immunol. 2024 Jan 4;14:1294919. doi: 10.3389/fimmu.2023.1294919. eCollection 2023. Front Immunol. 2024. PMID: 38239366 Free PMC article. Review.
References
-
- Rusfianti M, Wirohadidjodjo YW. Dermatosurgical techniques for repigmentation of vitiligo. Int J Dermatol. 2006;45:411–417. - PubMed
-
- Olsson MJ, Juhlin L. Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol. 1998;138:644–648. - PubMed
-
- van Geel N, Ongenae K, De Mil M, Naeyaert JM. Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: a pilot study. Dermatol Surg. 2001;27:873–876. - PubMed
-
- Olsson M, Juhlin L. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol. 2002;147:893–904. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous